You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
McKinsey
Dow
Express Scripts

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Patent: 10,376,578

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,376,578
Title:Compositions and methods for treating Crohn\'s disease and related conditions and infections
Abstract: In alternative embodiments, the invention provides a \"triple combination\" therapy for treating, ameliorating and preventing Crohn\'s Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne\'s disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn\'s Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn\'s Disease and complications of Crohn\'s Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne\'s disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNF.alpha. composition, or a composition capable of down-modulating TNF.alpha. activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti-Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.
Inventor(s): Agrawal; Gaurav (Manly, AU)
Assignee: Agrawal; Guarav (Manly, AU)
Application Number:15/483,702
Patent Claims:see list of patent claims

Details for Patent 10,376,578

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 001 2017-05-26   Start Trial Agrawal; Guarav (Manly, AU) 2032-06-04 RX search
Janssen Biotech SIMPONI ARIA golimumab INJECTABLE; INJECTION 125433 001 2013-07-18   Start Trial Agrawal; Guarav (Manly, AU) 2032-06-04 RX search
Centocor Ortho Biotech Inc SIMPONI golimumab INJECTABLE; INJECTION 125289 001 2009-04-24   Start Trial Agrawal; Guarav (Manly, AU) 2032-06-04 RX Orphan search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Agrawal; Guarav (Manly, AU) 2032-06-04 RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Agrawal; Guarav (Manly, AU) 2032-06-04 RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20   Start Trial Agrawal; Guarav (Manly, AU) 2032-06-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,376,578

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Colorcon
Johnson and Johnson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.